0
1. 12. 2022.
87P Infliximab use in patients with checkpoint inhibitor toxicities: A tertiary centre experience
87P Infliximab use in patients with checkpoint inhibitor toxicities: A tertiary centre experience
Ova stranica koristi kolačiće da bi vam pružila najbolje iskustvo
Saznaj više